MEDACTA GROUP S.A. SF-,10

Medacta has appointed Riccardo Fava as group VP investor relations, sustainability & media relations effective 1 October 2026. He reports directly to CEO Francesco Siccardi and will take responsibility for investor, analyst and media relations as well as for sustainability strategy and reporting. The company cites continued growth, particularly in the US, as the reason for the new appointment; the stock traded about 1 percent higher at times. » More on finanzen.net

Medacta reported currency-adjusted revenue growth of around 10% in H1 2026 to EUR 368m and an adjusted EBITDA of EUR 97m (currency-adjusted margin 27.8%). Gross margin fell to 65.2% and free cash flow turned negative at -EUR 18.6m due to inventory build-up and investments; operating cash flow also declined. Management confirmed the full-year guidance (currency-adjusted revenue growth 10–14% and margin improvement) and expects improvement in H2 supported by a US recovery, shipments to India and easier comparables. The stock fell 3.43% and traded near its 52-week low as investors highlighted weaker cash generation and margin trends. » More on de.investing.com

Medacta reports H1 2026 revenue of €368.0m (about +7%) and adjusted EBITDA of €97.4m (-1.4%); the margin fell to 26.5% from 28.7% a year earlier. Net profit declined to €41.9m, mainly because a one-off takeover gain from 2025 (Parcus Medical) did not recur. CEO Francesco Siccardi cited an unexpected slowdown in the US market and higher transport costs as headwinds; full-year targets remain confirmed with a revenue target of +10–14% and an adjusted EBITDA margin improvement of ~50 basis points, and medium-term annual revenue growth of 12–15% is targeted for 2024–2027. » More on finanzen.net